GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BioNexus Gene Lab Corp (NAS:BGLC) » Definitions » Interest Coverage

BioNexus Gene Lab (BioNexus Gene Lab) Interest Coverage : 0 (At Loss) (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is BioNexus Gene Lab Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. BioNexus Gene Lab's Operating Income for the three months ended in Mar. 2024 was $-0.08 Mil. BioNexus Gene Lab's Interest Expense for the three months ended in Mar. 2024 was $-0.01 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for BioNexus Gene Lab's Interest Coverage or its related term are showing as below:


BGLC's Interest Coverage is not ranked *
in the Chemicals industry.
Industry Median: 9.71
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


BioNexus Gene Lab Interest Coverage Historical Data

The historical data trend for BioNexus Gene Lab's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

BioNexus Gene Lab Interest Coverage Chart

BioNexus Gene Lab Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial N/A 115.82 81.23 - -

BioNexus Gene Lab Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 64.50 -

Competitive Comparison of BioNexus Gene Lab's Interest Coverage

For the Specialty Chemicals subindustry, BioNexus Gene Lab's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioNexus Gene Lab's Interest Coverage Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's Interest Coverage distribution charts can be found below:

* The bar in red indicates where BioNexus Gene Lab's Interest Coverage falls into.



BioNexus Gene Lab Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BioNexus Gene Lab's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, BioNexus Gene Lab's Interest Expense was $-0.01 Mil. Its Operating Income was $-2.59 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.10 Mil.

BioNexus Gene Lab did not have earnings to cover the interest expense.

BioNexus Gene Lab's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Here, for the three months ended in Mar. 2024, BioNexus Gene Lab's Interest Expense was $-0.01 Mil. Its Operating Income was $-0.08 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.09 Mil.

BioNexus Gene Lab did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


BioNexus Gene Lab  (NAS:BGLC) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


BioNexus Gene Lab Interest Coverage Related Terms

Thank you for viewing the detailed overview of BioNexus Gene Lab's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


BioNexus Gene Lab (BioNexus Gene Lab) Business Description

Traded in Other Exchanges
N/A
Address
No. 8 Jalan Kerinchi, The Vertical Business Suite II, Unit 02, Level 10, Tower B, Avenue 3, Bangar South, Kuala Lumpur, SGR, MYS, 59200
BioNexus Gene Lab Corp is an emerging molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management. It focuses on developing and marketing safe, effective, and non-invasive blood tests for the early detection of diseases. The company's non-invasive blood tests analyze changes in ribonucleic acid (or RNA) to detect the potentiality of 11 different diseases. These diseases include eight cancers (nasopharyngeal, lung, liver, stomach, breast, cervical, prostate, and colon), two bowel diseases (colitis and Crohn), and osteoarthritis.
Executives
Chak Hua Yew director 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Yeat Min Fong director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Teng Fook Fong director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Chee Keong Yap director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Boon Teong Teoh director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Yee Meng Wong director, officer: President 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Wei Li Leong officer: Chief Financial Officer 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Chai Ping Lin director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Tai Tan Liong director, officer: Chief Operating Officer 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Sook Keng Yeoh director, officer: Chief Executive Officer 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200